Scott M. Schuetze,Michael Rothe,Pam K. Mangat,Elizabeth Garrett‐Mayer,Funda Meric‐Bernstam,Carmen Calfa,Laura Catherine Farrington,Michael B. Livingston,Kristopher Wentzel,Deepti Behl,Yelena Kier,Alissa Marr,Margaret von Mehren,Joshua Z. Press,Ramya Thota,Gina N. Grantham,Abigail Gregory,Dominique C. Hinshaw,Susan Halabi,Richard L. Schilsky
出处
期刊：JCO precision oncology [American Society of Clinical Oncology] 日期：2024-07-01卷期号： (8)
Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with soft tissue sarcoma with cyclin-dependent kinase 4 (
爱静静
VDC
热心路人
Xiaoxiao
ccc
YifanWang
petrichor
苗条绝义
Emon
NicoLi
SYLH
Leon
迟大猫
杳鸢
一夜很静
小林太郎
SONGYEZI
kento
latiao99
Qi
皖公网安备34019202002308
